SCHEMBL2912761

SCHEMBL2912761

C[C@@H](O)[C@](O)(Cn1cncn1)c1ccc(F)cc1F

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 17/20 0.70
CYP2C9 P11712 11/20 0.70
CYP2C19 P33261 11/20 0.70
LMNA P02545 2/20 0.70
CYP2B6 P20813 1/20 0.70
CYP3A5 P20815 1/20 0.70
CYP3A7 P24462 1/20 0.70
MAPK1 P28482 1/20 0.70
CYP3A43 Q9HB55 1/20 0.70
CYP46A1 Q9Y6A2 1/20 0.70
HSP90AA1 P07900 1/20 0.69
CYP19A1 P11511 1/20 0.69
CYP11B1 P15538 1/20 0.69
CYP11B2 P19099 1/20 0.69
ADRA1A P35348 1/20 0.69
CYP51A1 Q16850 1/20 0.69
CYP1A2 P05177 6/20 0.64
CYP2D6 P10635 6/20 0.64
KCNH2 Q12809 3/20 0.59
ABCG2 Q9UNQ0 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2566503 1.00 CYP3A4 (0.70) CYP3A4CYP2C9CYP2C19LMNACYP2B6
SCHEMBL30485092 1.00 CYP3A4 (0.70) CYP3A4CYP2C9CYP2C19LMNACYP2B6
SCHEMBL7478959 1.00 CYP3A4 (0.70) CYP3A4CYP2C9CYP2C19LMNACYP2B6
SCHEMBL1824105 1.00 CYP3A4 (0.70) CYP3A4CYP2C9CYP2C19LMNACYP2B6
SCHEMBL7537507 1.00 CYP3A4 (0.70) CYP3A4CYP2C9CYP2C19LMNACYP2B6
SCHEMBL18717940 1.00 CYP3A4 (0.70) CYP3A4CYP2C9CYP2C19LMNACYP2B6
SCHEMBL10597737 1.00 CYP3A4 (0.70) CYP3A4CYP2C9CYP2C19LMNACYP2B6
SCHEMBL29357899 0.93 CYP3A4 (0.63) CYP3A4CYP2C9CYP2C19LMNACYP2B6
SCHEMBL28847757 0.93 CYP3A4 (0.63) CYP3A4CYP2C9CYP2C19LMNACYP2B6
SCHEMBL28847754 0.93 CYP3A4 (0.63) CYP3A4CYP2C9CYP2C19LMNACYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3564207-B1 METHOD FOR PRODUCING ALCOHOL COMPOUND KANEKA CORP (JP) 2021-09-15 EP claimed
US-10919829-B2 Method for producing alcohol compound KANEKA CORPORATION (JP) 2021-02-16 US claimed
EP-3564207-A1 METHOD FOR PRODUCING ALCOHOL COMPOUND Kaneka Corporation (JP) 2019-11-06 EP claimed
US-20190300465-A1 METHOD FOR PRODUCING ALCOHOL COMPOUND KANEKA CORPORATION (JP) 2019-10-03 US claimed
US-12018010-B2 Method for preparing efinaconazole using ionic liquid as medium DAEBONG LS CO., LTD. (KR) 2024-06-25 US disclosed
US-12018010-B2 Method for preparing efinaconazole using ionic liquid as medium DAEBONG LS CO., LTD. (KR) 2024-06-25 US disclosed
US-12018010-B2 Method for preparing efinaconazole using ionic liquid as medium DAEBONG LS CO., LTD. (KR) 2024-06-25 US disclosed
EP-3915981-B1 METHOD FOR PREPARATION OF EFINACONAZOLE IN IONIC LIQUID MEDIUM DAEBONG LS CO LTD (KR) 2024-04-03 EP disclosed
US-20220127245-A1 METHOD FOR PREPARATION OF EFINACONAZOLE IN IONIC LIQUID MEDIUM DAEBONG LS CO., LTD. (KR) 2022-04-28 US disclosed
EP-3666762-B1 METHOD FOR PRODUCING EPOXY ALCOHOL COMPOUND SUMITOMO CHEMICAL CO (JP) 2022-04-06 EP disclosed
EP-3915981-A1 METHOD FOR PREPARATION OF EFINACONAZOLE IN IONIC LIQUID MEDIUM Daebong LS Co., Ltd. (KR) 2021-12-01 EP disclosed
EP-3564207-B1 METHOD FOR PRODUCING ALCOHOL COMPOUND KANEKA CORP (JP) 2021-09-15 EP disclosed
US-6133485-A Asymmetric synthesis of 2-(2,4-difluorophenyl)-1-heterocycl-1-yl butan-2,3-diols SYNPHAR LABORATORIES, INC. (CA) 2000-10-17 US disclosed
WO-1999052840-A1 ASYMMETRIC SYNTHESIS OF 2-ARYL-1-SUBSTITUTED BUTAN-2,3-DIOLS NAEJA PHARMACEUTICAL INC. (US) 1999-10-21 WO disclosed
EP-0728752-A1 Triazole compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-08-28 EP disclosed
EP-0659751-A1 Optically active azole derivatives, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1995-06-28 EP disclosed
US-5405861-A Fungicides TAKEDA CHEMICAL INDUSTRIES, CO., LTD. (JP) 1995-04-11 US disclosed
US-5387599-A Fungicide TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1995-02-07 US disclosed
EP-0446877-A2 Triazoles, their production and use Takeda Chemical Industries, Ltd. (JP) 1991-09-18 EP disclosed
EP-0421210-A2 Triazole compounds, their production and use Takeda Chemical Industries, Ltd. (JP) 1991-04-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018010-B2 Method for preparing efinaconazole using ionic liquid as medium CYP3A5, CYP3A7, NEFM CYP3A4 4/4885CYP2C9 20/4885CYP2C19 15/4885
US-20220127245-A1 METHOD FOR PREPARATION OF EFINACONAZOLE IN IONIC LIQUID MEDIUM CYP3A5, NEFM, IL5 CYP3A4 5/4885CYP2C9 24/4885CYP2C19 17/4885
US-10919829-B2 Method for producing alcohol compound ADH1A, ADH1C, MEP1B CYP3A4 758/4885CYP2C9 1512/4885CYP2C19 1658/4885
US-20190300465-A1 METHOD FOR PRODUCING ALCOHOL COMPOUND ADH1A, ADH1C, MEP1B CYP3A4 758/4885CYP2C9 1512/4885CYP2C19 1658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.